In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Johnson & Johnson, with a price target of $253.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason Gerberry has given his Hold rating due to a combination of factors tied to Johnson & Johnson’s improved but still balanced outlook. He raises long-term revenue and earnings forecasts on the back of stronger expectations for key oncology assets such as Tecvayli and Inlexzo, as well as longer treatment durations for Darzalex, which collectively lift projected growth and justify a higher price objective and valuation multiple.
At the same time, he sees the stock already trading near his revised target, limiting potential upside despite JNJ’s attractive, low‑risk profile as a diversified, patent‑secure pharma and MedTech leader. The favorable loss‑of‑exclusivity runway and defensive characteristics support a premium multiple, but that is offset by valuation constraints and ongoing litigation overhangs, leading him to conclude that a Neutral stance is appropriate.
According to TipRanks, Gerberry is a 5-star analyst with an average return of 17.9% and a 63.58% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Eli Lilly & Co, and Teva Pharmaceutical.
In another report released on February 24, DBS also maintained a Hold rating on the stock with a $240.00 price target.